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Introduction
Diabetes Mellitus is a chronic metabolic disease characterized by elevated blood glucose
levels. This progressive disorder can lead to severe end organ damage, including heart disease,
stroke, blindness, diabetic retinopathy, cataracts, glaucoma, kidney disease, as well as blood vessel
and nerve damages leading to amputation. It is important to prevent or control diabetes with
effective treatment due to the extent of the complications associated with uncontrolled diabetes.
According to the World Health Organization, 422 million adults in the world have diabetes with
1.5 million deaths attributable to this disease annually. There are two types of diabetes mellitus—
type 1 diabetes mellitus (T1DM), in which insulin is no longer adequately produced by the
pancreas, and type 2 diabetes mellitus (T2DM), in which the body is unable to effectively utilize
the diminishing insulin supply produced by the pancreas. The Centers for Disease Control and
Prevention (CDC) states that T2DM accounts for up to 95% of all diagnosed cases of diabetes.2
Focusing on therapy, many options are available for treating T2DM; however, of the
numerous treatment choices, determining the most effective disease control is paramount. T2DM
therapeutic measures includes lifestyle modifications, such as eating healthfully, exercising
regularly, and losing excess weight. In addition, medicines are also prescribed to lower blood sugar
to help prevent and delay complications. While the use of prescription medications to treat T2DM
is a widely accepted and effective intervention, recent studies have shown that Roux-en-Y gastric
bypass procedure can be an alternate and potentially more effective treatment. Although it is
primarily used for bariatric therapy, Roux-en-Y gastric bypass surgery is currently being studied
as an option to aid in glycemic control in adults with T2DM.
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This research paper explores the effectiveness of Roux-en-Y gastric bypass surgery
compared to pharmacologic therapy for improving the plasma glucose and glycosylated
hemoglobin (HbA1c) levels in obese T2DM patients.
Discussion
Twelve articles were analyzed to determine if the Roux-en-Y gastric bypass procedure or
traditional management with medication is most effective to control T2DM. These studies
compared the effectiveness of Roux-en-Y gastric bypass surgery to pharmacologic therapy in
reducing HbA1c and controlling T2DM in obese patients. Additionally, they examined the
effectiveness of Roux-en-Y gastric bypass surgery compared to other bariatric surgeries in
reducing HbA1c.
In a study conducted by Zhang et al in 2016, the effectiveness and safety of laparoscopic
Roux-en-Y gastric bypass for the treatment of T2DM were investigated. The goal was to measure
the effects on diabetes remission and metabolic syndrome in individuals with T2DM after
undergoing gastric bypass surgery. Patient demographics, including body mass index (BMI),
diabetes disease duration, and blood lipid levels were prospectively collected and analyzed. Of the
85 patients studied, the pre-operative BMI for each patient was above 28 kg/m2, indicating obesity,
and the mean HbA1c level was 8.32%, consistent with uncontrolled T2DM.3 After the patients
received Roux-en-Y gastric bypass surgery, their blood lipid levels were checked at 6 months, 12
months and 18 months appointments post-operatively. The evidence showed significant changes
in their preoperative blood lipid levels; blood cholesterol levels decreased at 12 and 18 months,
triglyceride levels decreased at 6, 12, and 18 months, LDL levels decreased at 12 and 18 months.
Moreover, HbA1c and plasma glucose were significantly reduced after this gastric bypass surgery.
Thus, the evidence demonstrated that Roux-en-Y gastric bypass surgery was effective in
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improving the HbA1c levels in obese T2DM patients. However, this study was limited by the lack
of generalizability of the results to different populations, especially patients with BMIs of <28
kg/m2.
As noted, Roux-en-Y gastric bypass can help to alleviate the multiple factors causing
metabolic syndrome, including hyperlipidemia, diabetes type 2, hypertension, and elevated
visceral fat. To address the persistence of those changes, Cohen et al in 2017, examined whether
Roux-en-Y gastric bypass improved metabolic outcomes in obese diabetic patients for at least five
years. They found that Roux-en-Y gastric bypass performed in T2DM participants with a BMI of
30-40 kg/m2 increased the probability of achieving T2DM remission in a statistically significant
way.12 Both HbA1c levels and blood pressure decreased, and HDL levels increased. This bariatric
surgery effectively controlled the three major endpoints of metabolic syndrome. Thus, this study
confirmed that the Roux-en-Y gastric bypass procedure can effectively reduce plasma blood
glucose and HbA1c levels in obese T2DM patients. It was limited by the maximum length of
follow up of five years post-operative. Longer follow-up periods comparing Roux-en-Y gastric
bypass surgery with medical management alone could identify their respective micro- and
macrovascular outcomes in T2DM patients.
Other bariatric surgeries are available for patients with morbid obesity, hence the need to
evaluate their effects on HbA1c levels and remission of T2DM. Courcoulas et al compared the
remission of T2DM following different surgical and nonsurgical treatments. At 3 years, T2DM
remission was achieved in 40% of patients after Roux-en-Y gastric bypass surgery, 29% after
sleeve gastrectomy, and 0% with non-surgical management. The Roux-en-Y gastric bypass group
had the greatest change in both HbA1c and fasting blood sugar levels from baseline.8 It was
superior to sleeve gastrectomy for both lowering HbA1c levels and inducing remission in type 2
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diabetics. Non-surgical management compared to surgery was ineffective in inducing remission
in type 2 diabetics. Furthermore, not only was Roux-en-Y gastric bypass surgery more effective
for reducing HbA1c levels in obese T2DM patients than diabetes medications alone, it was also
more effective than sleeve gastrectomy operations for inducing T2DM remissions. Greater than
40% of the sample were individuals with class I obesity (BMI of 30-<35), a strength in
generalizability because the literature was largely lacking such data. However, the small sample
size of 61, negatively affected the study’s power, and thus, its ability to detect statistically
significant differences. In another study from 2015, Musella et al compared the rates of remission
achieved in morbidly obese T2DM patients after Roux-en-Y gastric bypass versus sleeve
gastrectomy. Both surgical procedures were effective.9 However, the Roux-en-Y gastric bypass
procedure performed better than the sleeve gastrectomy at 1 year with diabetes remission rates of
85.4% versus 60.9%.
Roux-en-Y gastric bypass was also compared to bariatric procedures for its ability to
reduce HbA1c and to induce diabetes remission. Purnell et al examined T2DM remission after
Roux-en-Y gastric bypass versus laparoscopic gastric banding. Remission of diabetes at one year
after Roux-en-Y gastric bypass was 71.0%, whereas remission after laparoscopic gastric banding
was 29.9%.10 This study was limited by its relatively short follow-up period of 12 months and a
dropout rate of 15%. Nonetheless, Roux-en-Y gastric bypass surgery was more effective than
gastric banding for inducing and maintaining remission in type 2 diabetics.
So far, the prevailing evidence in most studies shows that the Roux-en-Y gastric bypass
procedure may not only cause significant reductions of HbA1c, but also complete remissions of
T2DM. Supporting that evidence are results from Carranza et al in 2017. They examined the rate
of T2DM remission 4 years following gastric bypass in a real-life clinic cohort in the U.S. Veterans
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Health Care System. Eighty-eight percent of patients experienced improvement or remission of
diabetes 4 years post the Roux-en-Y gastric bypass surgery. In fact, diabetes remission was
achieved by 15% of patients at 6 months post-operation, a rate that increased to 49% at 4 years
post-operation.7 These findings confirm those found in the other studies; Roux-en-Y gastric bypass
surgery as an intervention in obese T2DM can lead to reduction in HbA1c and even remission.
However, the Carranza et al study was limited because it was a retrospective study and it was
conducted in the US Veterans Health Care system, in which the majority of participants were war
veterans with low-income; as such, these results may not be entirely generalizable to other
populations.
A study by Kaska et al in 2014 characterized the dynamics of T2DM remission in patients
with BMI <35 and >35 kg/m2 after Roux-en-Y gastric bypass surgery. T2DM remission was
determined by fasting plasma glucose and HbA1c levels. T2DM regression was observed in 80%
of patients with a BMI <35 kg/m2, and 83% of patients with a BMI >35 kg/m2 one year after the
surgery. Two and three years after the surgery, the T2DM regression plateaued to 80% of the
patients in both groups, 4 establishing that Roux-en-Y gastric bypass surgery reduces HbA1c levels
and can lead to T2DM remission in patients with BMI<35 and >35 kg/m2.
The effectiveness of Roux-en-Y gastric bypass surgery to reduce HbA1c levels and induce
remission may not be generalizable to obese type 2 diabetics of all ethnicities. Chong et al
conducted a study that addressed this concern. They investigated the impact of Roux-en-Y gastric
bypass and intensive medical management in an Asian population and a non-Asian American
(United States) cohort; specifically, patients who were Taiwanese were compared with Americans.
At 24 months, none of the participants in the intensive medical management groups achieved
partial or complete diabetes remission. In contrast, the Roux-en-Y groups showed significant
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partial or complete remission in 29% of Taiwanese cohort and 14% in the American cohort.11
These findings confirm that T2DM remission or HbA1c reductions occurring with Roux-en-Y
gastric bypass are generalizable to more than one ethnicity. In addition, the remission rates suggest
that this surgery is more effective in the Taiwanese population. This study was limited by its small
sample size, 120 participants.
In the aforementioned studies, many patients continued their diabetes medications after the
Roux-en-Y gastric bypass procedure. Ammori et al in 2014 studied the effectiveness of stopping
glucose-lowering treatment at the time of gastric bypass surgery in T2DM patients. After surgery
patients still had significant weight losses with a mean reduction in BMIs by 16.4% and reductions
in HbA1c of 23.6%.5 HbA1c reductions were maintained up to 24 months post-operatively. Thus,
patients were able to maintain their HbA1c reduced status post-operatively through weight
reduction alone and did not need to restart hypoglycemic agents. Although this study was limited
by its retrospective design, it provided evidence that Roux-en-Y gastric bypass surgery in obese
T2DM patients is effective for controlling HbA1c levels, without the reinstitution of diabetes
medications.
While it is clear that T2DM medications may not be necessary for HbA1c control after
Roux-en-Y gastric bypass in certain patients, continuing lifestyle modifications and medications
after surgery can provide effective control of diabetes. In 2018, Ikramuddin et al compared the
durability of Roux-en-Y gastric bypass added to intensive lifestyle and medical management to
lifestyle-medication management only for control of diabetes. Five years after the procedure, 55%
of participants in the gastric bypass group versus 14% of participants in the lifestyle-medical
management group achieved HbA1c of less than 7.0% (P=0.002).6 The target goal of HbA1c less
than 7.0% was maintained by 70% of patients at five years. Thus, if intensive lifestyle
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modifications and medical management are not effective in controlling diabetes adequately, Rouxen-Y gastric bypass may help to bridge that gap. The generalizability of these findings is limited
because the mean baseline HbA1c concentration in the participants was 9.5%, which indicated
relatively poorly controlled hyperglycemia at baseline; thus, whether the results would be different
with better controlled baseline hyperglycemia is unknown for this comparison.
Conclusion
The currently available studies provide evidence that Roux-en-Y gastric bypass surgery
effectively reduces the plasma glucose and HbA1c levels in obese patients with T2DM. Moreover,
Roux-en-Y gastric bypass surgery can promote the regression of T2DM in obese patients. These
findings support the practice of referring obese T2DM patients for Roux-en-Y gastric bypass
surgery in order to control and possibly induce remission of their diabetes. In fact, this bariatric
surgery may be more beneficial for obese diabetics than following the current practice of
prescribing T2DM medications. Roux-en-Y gastric bypass surgery is, at a minimum, an effective
alternative treatment for obese T2DM patients, and may become a preferred treatment option.
Whether Roux-en-Y gastric bypass without glucose-lowering medications would provide more
significant HbA1c reduction than traditional pharmacologic therapy needs confirmation with
additional studies.
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